TITLE:
Novel Approach to Chemotherapy and Administration Selection with Metronomic/Fractionated Dosing
AUTHORS:
Aaron J. Smith, John Oertle, Dino Prato
KEYWORDS:
Metronomic Dosing, Chemotherapy, Multidrug Resistance, Neutropenia, Lymphocytopenia, Insulin, Biomarkers, Cognitive Changes
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.6 No.5,
May
27,
2015
ABSTRACT:
Metronomic dosing of chemotherapy was introduced in the early 2000s and
has since gained recognition as a potential game changer in the manner of which
chemotherapy can be administered. There are several known candidates for
metronomic dosing of chemotherapy with the potential for many more to be
elucidated in the future. Minimized overall side effects, longer durations of
treatment, potential minimization of multidrug resistance (MDR) mutations,
potential less refractory responses, and the potential to safely use more than
one chemotherapy treatments also make metronomic dosing of chemotherapy
attractive. Metronomic dosing reduces common side effects and has the potential
to reduce neutropenia, lymphocytopenia, and cognitive changes associated with
maximum tolerated dosages (MTD). Methods of enhancing chemotherapy including
fasting and administration of insulin are also discussed. Metronomic dosing
combined with a patient’s molecular profile derived from biomarkers is
particularly exciting. It holds significant potential with regard to
administrating the most relevant chemotherapies and offers maximal beneficial
results.